These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Simpson L; Galanis E Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364 [TBL] [Abstract][Full Text] [Related]
63. Antiangiogenic and antitumor potential of berbamine, a natural CaMKIIγ inhibitor, against glioblastoma. Kim YJ; Han JM; Jung HJ Biochem Biophys Res Commun; 2021 Aug; 566():129-134. PubMed ID: 34119825 [TBL] [Abstract][Full Text] [Related]
64. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Sorensen AG; Emblem KE; Polaskova P; Jennings D; Kim H; Ancukiewicz M; Wang M; Wen PY; Ivy P; Batchelor TT; Jain RK Cancer Res; 2012 Jan; 72(2):402-7. PubMed ID: 22127927 [TBL] [Abstract][Full Text] [Related]
65. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Lucio-Eterovic AK; Piao Y; de Groot JF Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589 [TBL] [Abstract][Full Text] [Related]
66. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Iwamoto FM; Lamborn KR; Robins HI; Mehta MP; Chang SM; Butowski NA; Deangelis LM; Abrey LE; Zhang WT; Prados MD; Fine HA Neuro Oncol; 2010 Aug; 12(8):855-61. PubMed ID: 20200024 [TBL] [Abstract][Full Text] [Related]
67. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Hall WA; Vallera DA Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029 [TBL] [Abstract][Full Text] [Related]
71. Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside. Shamshiripour P; Hajiahmadi F; Lotfi S; Esmaeili NR; Zare A; Akbarpour M; Ahmadvand D Front Immunol; 2022; 13():859633. PubMed ID: 35757736 [TBL] [Abstract][Full Text] [Related]
72. Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations. Nery de Albuquerque Rego G; da Hora Alves A; Penteado Nucci M; Bustamante Mamani J; Anselmo de Oliveira F; Gamarra LF Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599834 [TBL] [Abstract][Full Text] [Related]
73. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Kloepper J; Riedemann L; Amoozgar Z; Seano G; Susek K; Yu V; Dalvie N; Amelung RL; Datta M; Song JW; Askoxylakis V; Taylor JW; Lu-Emerson C; Batista A; Kirkpatrick ND; Jung K; Snuderl M; Muzikansky A; Stubenrauch KG; Krieter O; Wakimoto H; Xu L; Munn LL; Duda DG; Fukumura D; Batchelor TT; Jain RK Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4476-81. PubMed ID: 27044098 [TBL] [Abstract][Full Text] [Related]
74. Current role of anti-angiogenic strategies for glioblastoma. Thomas AA; Omuro A Curr Treat Options Oncol; 2014 Dec; 15(4):551-66. PubMed ID: 25173555 [TBL] [Abstract][Full Text] [Related]
75. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Pore N; Gupta AK; Cerniglia GJ; Maity A Neoplasia; 2006 Nov; 8(11):889-95. PubMed ID: 17132220 [TBL] [Abstract][Full Text] [Related]
76. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy. Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012 [TBL] [Abstract][Full Text] [Related]
77. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451 [TBL] [Abstract][Full Text] [Related]